Kamada Highlights CYTOGAM® Study Results Presented at the 2026 ISHLT Annual Meeting
false
÷îäãò áò"î
2
380
KAMADA LTD
Corporation no:
511524605
16035
Israel Securities Authority
Tel Aviv Stock Exchange
C002
(
Public
)
Reported via MAGNA:
13/07/2026
www.isa.gov.il
www.tase.co.il
Reference:
2026-02-066195
Time of broadcast:
11:01
11:01
The corporation scheduled the publication of the report to
13/07/2026 14:02
Immediate Report
Regulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000
The corporation is a foreign private issuer as defined by U.S. Securities Laws.
Attached hereto is a report on
Kamada Highlights CYTOGAM® Study Results Presented at the 2026 ISHLT Annual Meeting
ea029777101-6k_kamadaEDGAR1_Bannerless_isa.pdf
References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Stock Exchange/Market:
TASE
Date of revision of form structure:
06/08/2024
Address:
Holtzman 2
4081
,
Rehovot
7670402
ISRAEL
,
Tel:
08-9406472
,
Fax:
08-9406473
E-mail address:
Mosheb@kamada.com
Company site:
www.kamada.com
Previous names of reporting entity:
Name of the Signatory:
îéøì àáéøï
Position of Signatory in the reporting corporation:
Financial Controller
Name of Employer Company:
Address:
Derech Hayam
38/26
,
Ashqelon
7800289
Telephone:
054-5392955
Facsimile:
E-mail:
aviranm@kamada.com
1